Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Overseas Growth Boosts Combined Sales of Four Major Drug Makers
November 6, 2014
-
TRENDS Chugai Led in Research Grants Payment in FY2013; Grants Fell Among Major Drug Makers
November 5, 2014
-
BUSINESS Astellas’s First-Half Sales Rise 9.3%, Operating Profit 61.8%
November 4, 2014
-
BUSINESS Takeda Aims for Consecutive Sales Growth through FY2022
October 31, 2014
-
BUSINESS GPCR Consortium, an International Partnership of Industry and Academia, Established: Ono
October 30, 2014
-
ORGANIZATION JPMA to Launch Compound Library Joint Purchasing Initiative; Full-Scale Purchasing to Begin in FY2015
October 29, 2014
-
BUSINESS Pfizer Japan Gearing Up for Reorganization in December, Pres. Umeda to Double as Head of New Unit
October 28, 2014
-
BUSINESS Japan Arm of Hengrui Medicine Files Campto Generic for Approval
October 27, 2014
-
REGULATORY Chuikyo Begins Discussions on Patient-Initiated Mixed-Care System
October 24, 2014
-
REGULATORY Online Document Filings for Healthcare Product Import/Export Possible from November
October 23, 2014
-
ORGANIZATION Japan CRO Association Nearing Remote Verification Agreement with Cancer Treatment Center
October 22, 2014
-
REGULATORY Health Ministry Eyes Future Genomic Data Registration at National Medical Centers
October 21, 2014
-
BUSINESS Astellas to End License Agreement with US Venture Company for AD Treatments
October 20, 2014
-
BUSINESS Bayer AG Aims to Achieve Japan Sales of 300 Billion Yen by 2017
October 17, 2014
-
REGULATORY NIBIO to Begin Drug Seed Optimization Project from FY2015
October 16, 2014
-
REGULATORY 4 Die after Taking SGLT-2 Inhibitors, Causality under Scrutiny
October 15, 2014
-
BUSINESS Parexel CEO Hails Rise of Partnership-Based Outsourcing in Japan
October 14, 2014
-
ACADEMIA St. Marianna Hospital Elbows Drug Makers to Reveal Detailing Costs Embedded in Drug Prices
October 10, 2014
-
BUSINESS GSK to Market Authorized Generics through Aspen Japan Unit
October 10, 2014
-
REGULATORY MOF Panel to Pitch Reference Pricing for Long-Listed Drugs, Price Cut in FY2015
October 9, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…